Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies (scientific article)

cites work (P2860)

Q94479700	"It made me more confident that I have it under control": Patient and provider perspectives on moving to a two-drug ART regimen in the United States and Spain
Q36920755	"What I got to go through": normalization and HIV-positive adolescents
Q39651697	'Got a room for me?' Housing experiences of older adults living with HIV/AIDS in Ottawa.
Q39952024	A Plausible Causal Model of HAART-Efficacy Beliefs, HIV/AIDS Complacency, and HIV-Acquisition Risk Behavior Among Young Men Who Have Sex with Men
Q36282340	A Systematic Review of the Effects of Exercise Interventions on Body Composition in HIV+ Adults.
Q39440887	A conceptual framework for understanding chronic pain in patients with HIV.
Q35903160	A cost analysis of an Internet-based medication adherence intervention for people living with HIV.
Q36611180	A curative regimen would decrease HIV prevalence but not HIV incidence unless targeted to an ART-naïve population
Q51561039	A decade of sperm washing: clinical correlates of successful insemination outcome.
Q61865978	A decision tree to help determine the best timing and antiretroviral strategy in HIV-infected patients
Q38038817	A dedicated clinic for HIV-positive individuals over 50 years of age: a multidisciplinary experience
Q34999270	A degenerative retinal process in HIV-associated non-infectious retinopathy
Q40679206	A global survey of HIV-positive people's attitudes towards cure research.
Q33999798	A higher correlation of HCV core antigen with CD4+ T cell counts compared with HCV RNA in HCV/HIV-1 coinfected patients
Q34388983	A history of alcohol dependence augments HIV-associated neurocognitive deficits in persons aged 60 and older
Q34163174	A mathematical model of comprehensive test-and-treat services and HIV incidence among men who have sex with men in the United States
Q34398159	A multicenter study of initiation of antiretroviral therapy and transmitted drug resistance in antiretroviral-naive adolescents and young adults with HIV in New York City
Q37588728	A review of nucleoside reverse transcriptase inhibitor use to prevent perinatal transmission of HIV.
Q35186765	A short tool to screen HIV-infected patients for mild neurocognitive disorders - a pilot study
Q28543626	A significant reduction in the frequency of HIV-1 drug resistance in Québec from 2001 to 2011 is associated with a decrease in the monitored viral load
Q33790492	A suicide gene approach using the human pro-apoptotic protein tBid inhibits HIV-1 replication
Q40238897	A tale of two countries: all-cause mortality among people living with HIV and receiving combination antiretroviral therapy in the UK and Canada
Q33888740	AIDS-related and non-AIDS-related mortality in the Asia-Pacific region in the era of combination antiretroviral treatment
Q34542179	Abnormal liver stiffness assessed using transient elastography (Fibroscan®) in HIV-infected patients without HBV/HCV coinfection receiving combined antiretroviral treatment
Q37972113	Accelerated aging and human immunodeficiency virus infection: emerging challenges of growing older in the era of successful antiretroviral therapy
Q39111499	Acceptability of Family-Centered Advanced Care Planning for Adolescents With HIV.
Q42270253	Achieving improvements across the HIV treatment cascade: a clinical management algorithm based on IAPAC's entry into and retention in care and antiretroviral therapy adherence guidelines
Q37373123	Acquired hypogammaglobulinemia in HIV-positive subjects after liver transplantation.
Q38259404	Advance directives among people living with HIV: room for improvement
Q83756320	Advocating for assistance with pregnancy planning in HIV-positive individuals and couples: an idea whose time has come
Q34982616	Age patterns of Kaposi's sarcoma incidence in a cohort of HIV-infected men
Q33684558	Age, comorbidities, and AIDS predict a frailty phenotype in men who have sex with men
Q30244296	Ageing and inflammation in patients with HIV infection.
Q46421066	Ageing faster with AIDS in Africa
Q56525467	Ageing with HIV: medication use and risk for potential drug-drug interactions
Q34094201	Aging of the human innate immune system in HIV infection
Q42288263	Aging with HIV and disability: the role of uncertainty.
Q39140930	Aging with HIV: a model of disability
Q38130178	Aging, antiretrovirals, and adherence: a meta analysis of adherence among older HIV-infected individuals
Q40591737	Alemtuzumab-induced elimination of HIV-1-infected immune cells
Q38582377	Alternative antiretroviral therapy formulations for patients unable to swallow solid oral dosage forms
Q38139529	Alzheimer's disease drug discovery: in vivo screening using Caenorhabditis elegans as a model for β-amyloid peptide-induced toxicity
Q87912949	An HIV-infected Patient with Confirmed Overlapping Complications of Severe Amebic Colitis and CMV Enteritis
Q37233549	An alternative methodology for the prediction of adherence to anti HIV treatment
Q35093196	Anal cancers among HIV-infected persons: HAART is not slowing rising incidence
Q44699469	Angina pectoris in patients with HIV/AIDS: prevalence and risk factors
Q26767476	Animal Models for HIV Cure Research
Q34267776	Animal models for viral infection and cell exhaustion
Q38043556	Animal models in virus research: their utility and limitations
Q33798442	Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody
Q40069947	Antiretroviral adherence among rural compared to urban veterans with HIV infection in the United States.
Q33713411	Antiretroviral drug costs and prescription patterns in British Columbia, Canada: 1996-2011.
Q37304808	Antiretroviral prescribing patterns in treatment-naïve patients in the United States.
Q37770721	Antiretroviral therapy and management of HIV infection
Q38185748	Antiretroviral therapy and preterm birth in HIV-infected women
Q36617684	Antiretroviral therapy in HIV-infected patients: a proposal to assess the economic value of the single-tablet regimen
Q37244544	Antiretroviral therapy suppressed participants with low CD4+ T-cell counts segregate according to opposite immunological phenotypes
Q42229844	Antiretroviral treatment-based cost saving interventions may offset expenses for new patients and earlier treatment start
Q40481227	ApoE ε4 Is Associated With Cognition, Brain Integrity, and Atrophy in HIV Over Age 60.
Q37604387	Apoptosis: a clinically useful measure of antiretroviral drug toxicity?
Q58816353	Approaches to improve the surveillance, monitoring, and management of noncommunicable diseases among HIV-infected persons (Preprint)
Q35150425	Ascertainment and verification of end-stage renal disease and end-stage liver disease in the north american AIDS cohort collaboration on research and design
Q39077480	Assessing and Refining Myocardial Infarction Risk Estimation Among Patients With Human Immunodeficiency Virus: A Study by the Centers for AIDS Research Network of Integrated Clinical Systems
Q37117076	Assessing willingness to test for HIV among men who have sex with men using conjoint analysis, evidence for uptake of the FDA-approved at-home HIV test
Q34408817	Associated factors for treatment delay in pulmonary tuberculosis in HIV-infected individuals: a nested case-control study
Q90538771	Association of Age-related Macular Degeneration With Mortality in Patients With Acquired Immunodeficiency Syndrome; Role of Systemic Inflammation
Q39086018	Association of Kidney Function and Early Kidney Injury With Incident Hypertension in HIV-Infected Women
Q50051702	Association of Retinal Vascular Caliber and Age-Related Macular Degeneration in Patients With the Acquired Immunodeficiency Syndrome
Q64272843	Association of Systemic Inflammation With Retinal Vascular Caliber in Patients With AIDS
Q34126545	Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study
Q46410663	Association of social determinants of health with self-rated health among Australian gay and bisexual men living with HIV.
Q62035584	Associations Between Antiretroviral Treatment and Avascular Bone Necrosis: The Swiss HIV Cohort Study
Q90281902	Associations of Urine Biomarkers with Kidney Function Decline in HIV-Infected and Uninfected Men
Q38811225	Astrocyte Elevated Gene-1 (AEG-1) and the A(E)Ging HIV/AIDS-HAND.
Q28080289	Atazanavir and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Patients: A Systematic Review
Q21134515	Attrition among human immunodeficiency virus (HIV)- infected patients initiating antiretroviral therapy in China, 2003-2010
Q39003106	Attrition from HIV care among adolescents and adults in a low-income setting
Q90053584	Autologous stem cell transplantation for lymphoma in HIV+ patients: higher rate of infections compared with non-HIV lymphoma
Q38924226	Barriers to HIV Medication Adherence as a Function of Regimen Simplification
Q47189547	Belief in Treatment as Prevention and Its Relationship to HIV Status and Behavioral Risk
Q48113493	Beyond the replication-competent HIV reservoir: transcription and translation-competent reservoirs.
Q59352065	Bioimaging predictors of rilpivirine biodistribution and antiretroviral activities
Q90110906	Biology of the human blood-nerve barrier in health and disease
Q37862747	Biomarkers of immune dysfunction following combination antiretroviral therapy for HIV infection
Q33678847	Body Composition and Metabolic Syndrome Components on Lipodystrophy Different Subtypes Associated with HIV
Q33614467	Brain dysfunction in the era of combination antiretroviral therapy: implications for the treatment of the aging population of HIV-infected individuals
Q36372161	Bridging the digital divide in HIV care: a pilot study of an iPod personal health record
Q33493535	Bridging the gap between adult and paediatric outcomes in HIV-1 vertically infected children: a single-centre comparison with adult data
Q35112836	Buprenorphine maintenance treatment retention improves nationally recommended preventive primary care screenings when integrated into urban federally qualified health centers
Q36736848	C-5-Modified Tetrahydropyrano-Tetrahydofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, including Darunavir
Q38005459	CCR5 inhibitors: emergence, success, and challenges
Q47094082	CD4 count and tuberculosis risk in HIV-positive adults not on ART: a systematic review and meta-analysis.
Q42246080	CD4 counts and mortality in virologically suppressed US veterans
Q34204890	CD4 lymphocyte dynamics in Tanzanian pulmonary tuberculosis patients with and without HIV co-infection
Q36219873	CD4/CD8 Ratio and KT Ratio Predict Yellow Fever Vaccine Immunogenicity in HIV-Infected Patients
Q28477027	Calculation of direct antiretroviral treatment costs and potential cost savings by using generics in the German HIV ClinSurv cohort
Q36526686	Can HIV reverse transcriptase activity assay be a low-cost alternative for viral load monitoring in resource-limited settings?
Q51675108	Can migrants from high-endemic countries cause new HIV outbreaks among heterosexuals in low-endemic countries?
Q48375195	Can we afford to offer pre-exposure prophylaxis to MSM in Catalonia? Cost-effectiveness analysis and budget impact assessment
Q34638912	Canadian HIV pregnancy planning guidelines
Q34238529	Canadian consensus statement on HIV and its transmission in the context of criminal law
Q34348772	Cancer incidence in the multicenter AIDS Cohort Study before and during the HAART era: 1984 to 2007
Q35838509	Cancer screening in patients infected with HIV.
Q41751842	Cardiovascular disease associated with the human immunodeficiency virus: an update
Q38206287	Cardiovascular disease in human immunodeficiency virus
Q38131061	Cardiovascular involvements in HIV-infected patients
Q44457745	Cardiovascular issues
Q40129344	Cardiovascular outcomes among HIV-infected veterans receiving atazanavir
Q90743449	Cardiovascular risk factors in HIV infected individuals: Comparison with general adult control population in Greece
Q37542914	Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons
Q91605816	Causative factors of liver fibrosis in HIV-infected patients. A single center study
Q40257849	Cause of death in HIV-infected patients in South Carolina (2005-2013).
Q61808718	Cause-specific mortality among HIV-infected people in Ontario, 1995-2014: a population-based retrospective cohort study
Q35823291	Causes of Death among AIDS Patients after Introduction of Free Combination Antiretroviral Therapy (cART) in Three Chinese Provinces, 2010-2011.
Q35169664	Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies
Q36798408	Cell-associated HIV RNA: a dynamic biomarker of viral persistence
Q42197898	Cerebrovascular events in HIV-infected patients: an analysis of a cohort of 3203 HIV+ patients during the times of cART.
Q36292161	Changes in mortality rates and causes of death in a population-based cohort of persons living with and without HIV from 1996 to 2012
Q37056028	Characteristics of an ambulatory palliative care clinic for HIV-infected patients
Q30424582	Characterization of LEDGF/p75 genetic variants and association with HIV-1 disease progression
Q45326055	Characterizing Human Immunodeficiency Virus Antiretroviral Therapy Interruption and Resulting Disease Progression Using Population-Level Data in British Columbia, 1996-2015.
Q36063587	Characterizing retention in HAART as a recurrent event process: insights into 'cascade churn'.
Q26825762	Chronic inflammation and the role for cofactors (hepatitis C, drug abuse, antiretroviral drug toxicity, aging) in HAND persistence
Q37024731	Chronic kidney disease associated with perinatal HIV infection in children and adolescents
Q38681101	Chronic kidney disease in Australian HIV-infected patients: analysis of the Australian HIV Observational Database
Q36522753	Cigarette Smokers are Less Likely to Have Undetectable Viral Loads: Results From Four HIV Clinics
Q42250758	Classification of human immunodeficiency virus-infected patients with chronic kidney disease using a combination of proteinuria and estimated glomerular filtration rate
Q36462119	Clinical and Virologic Outcomes After Changes in First Antiretroviral Regimen at 7 Sites in the Caribbean, Central and South America Network
Q41727026	Clinical characteristics and antiretroviral treatment of older HIV-infected patients
Q98284637	Clinical data combined with modelling and simulation indicate unchanged drug-drug interaction magnitudes in the elderly
Q37823558	Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era.
Q35088585	Clinical outcome of HIV-infected patients with discordant virological and immunological response to antiretroviral therapy
Q38833848	Clinical outcomes of HIV care delivery models in the US: a systematic review
Q38541809	Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection
Q38827420	Clinical setting-based smoking cessation programme and the quality of life in people living with HIV in Austria and Germany
Q40598881	Clinicopathological characteristics and management of prostate cancer in the human immunodeficiency virus (HIV)-positive population: experience in an Australian major HIV centre.
Q28537704	Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada
Q35036409	Co-morbidity, ageing and predicted mortality in antiretroviral treated Australian men: a quantitative analysis
Q50149700	Cocaine use may induce telomere shortening in individuals with HIV infection
Q38836472	Cognitive Impairment and Persistent CNS Injury in Treated HIV.
Q33736040	Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC).
Q46959264	Cohort profile: the Swiss HIV Cohort study
Q35925705	Commentary: Questioning the HIV-AIDS Hypothesis: 30 Years of Dissent
Q28541867	Comorbidities among the HIV-infected patients aged 40 years or older in Taiwan
Q37782179	Comparative Cost-Efficacy Analysis of Darunavir/ritonavir and Other Ritonavir-Boosted Protease Inhibitors for First-Line Treatment of HIV-1 Infection in the United States
Q36294152	Comparison of the Minimental State Examination Scale and the International HIV Dementia Scale in Assessing Cognitive Function in Nigerian HIV Patients on Antiretroviral Therapy
Q36653503	Comparisons of sexual behaviors and STD prevalence among older and younger individuals with HIV infection
Q41596952	Complexities and challenges of transition to adult services in adolescents with vertically transmitted HIV infection
Q37982768	Contemporary profile of oral manifestations of HIV/AIDS and associated risk factors in a Southeastern US clinic
Q33883560	Copy-years viremia as a measure of cumulative human immunodeficiency virus viral burden
Q33909483	Correlates of hypertension in patients with AIDS in the era of highly active antiretroviral therapy
Q37412246	Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting
Q35158119	Cost effectiveness of 'on demand' HIV pre-exposure prophylaxis for non-injection drug-using men who have sex with men in Canada
Q42213902	Cost effectiveness of darunavir/ritonavir combination antiretroviral therapy for treatment-naive adults with HIV-1 infection in Canada
Q33876681	Cost of Care for HIV-Infected Patients with Co-Occurring Substance Use Disorder or Psychiatric Disease: Report from a Large, Integrated Health Plan
Q89905960	Cost utility analysis of HIV pre exposure prophylaxis among men who have sex with men in Israel
Q36251587	Cost-effectiveness analysis of HIV treatment in the clinical practice of a public hospital in northern Italy
Q35111299	Cost-effectiveness analysis of antiretroviral therapy in a cohort of HIV-infected patients starting first-line highly active antiretroviral therapy during 6 years of observation
Q37344531	Cost-effectiveness analysis of coronary artery disease screening in HIV-infected men.
Q35602604	Cost-effectiveness analysis of initial HIV treatment under Italian guidelines
Q98945089	Cost-effectiveness analysis of pre-exposure prophylaxis for the prevention of HIV in men who have sex with men in South Korea: a mathematical modelling study
Q42706768	Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting
Q33916355	Cost-effectiveness of HIV screening in STD clinics, emergency departments, and inpatient units: a model-based analysis
Q92464598	Cost-effectiveness of a Medical Care Coordination Program for People With HIV in Los Angeles County
Q34995331	Cost-effectiveness of a nurse-based intervention (AIMS) to improve adherence among HIV-infected patients: design of a multi-centre randomised controlled trial
Q45369851	Cost-effectiveness of atazanavir/ritonavir compared with lopinavir/ritonavir in treatment-naïve human immunodeficiency virus-1 patients in Sweden
Q34427423	Cost-effectiveness of the third-agent class in treatment-naive human immunodeficiency virus-infected patients in Portugal
Q38114141	Costs and cost-effectiveness of HIV community services: quantity and quality of studies published 1986-2011.
Q33448243	Creating Effective Mobile Phone Apps to Optimize Antiretroviral Therapy Adherence: Perspectives From Stimulant-Using HIV-Positive Men Who Have Sex With Men.
Q37719593	Critical race theory as a tool for understanding poor engagement along the HIV care continuum among African American/Black and Hispanic persons living with HIV in the United States: a qualitative exploration
Q40512776	Cross sectional study of comorbidities and concomitant medications in a cohort of human immunodeficiency virus-infected patients
Q41757466	Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study
Q49727776	Current characteristics of hemophilia patients co-infected with HIV/HCV in Japan.
Q26749890	Current status and prospects of HIV treatment
Q36530478	Current strategies for improving access and adherence to antiretroviral therapies in resource-limited settings
Q37086478	Currently available medications in resource-rich settings may not be sufficient for lifelong treatment of HIV.
Q51766583	Cytomegalovirus-specific T-cells are associated with immune senescence, but not with systemic inflammation, in people living with HIV.
Q51846241	Death rates from human immunodeficiency virus and tuberculosis among American Indians/Alaska Natives in the United States, 1990-2009.
Q37118081	Decreasing excess mortality of HIV-infected patients initiating antiretroviral therapy: comparison with mortality in general population in China, 2003-2009
Q92480216	Design and validation of a predictive model for 1-year hospital admission in HIV patients on antiretroviral treatment
Q38384769	Developing a performance framework for measuring comprehensive, community-based primary healthcare for people with HIV.
Q36301862	Development and psychometric testing of a barriers to HIV testing scale among individuals with HIV infection in Sweden; The Barriers to HIV testing scale-Karolinska version
Q49228013	Development of an HPLC-UV assay method for the simultaneous quantification of nine antiretroviral agents in the plasma of HIV-infected patients
Q37156843	Diabetes and Hypertension among Patients Receiving Antiretroviral Treatment Since 1998 in Senegal: Prevalence and Associated Factors
Q61807328	Diabetes mellitus burden among people living with HIV from the Asia-Pacific region
Q40793633	Diagnostic accuracy of algorithms to identify hepatitis C status, AIDS status, alcohol consumption and illicit drug use among patients living with HIV in an administrative healthcare database
Q41927394	Differences in health-related quality of life between HIV-positive and HIV-negative people in Zambia and South Africa: a cross-sectional baseline survey of the HPTN 071 (PopART) trial
Q35408098	Differential levels of soluble inflammatory markers by human immunodeficiency virus controller status and demographics
Q33593633	Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure
Q40173720	Differential prevalence and correlates of whole blood Epstein-Barr virus DNA between HIV-positive and HIV-negative men who have sex with men in Shanghai, China
Q35741837	Differential signaling mechanism for HIV-1 Nef-mediated production of IL-6 and IL-8 in human astrocytes
Q37122279	Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy
Q36293125	Directly observed versus self-administered antiretroviral therapies: preference of HIV-positive jailed inmates in San Francisco
Q36083124	Disparities in HIV clinic care across Europe: findings from the EuroSIDA clinic survey
Q34499532	Disparities in the burden of HIV/AIDS in Canada
Q39713330	Distance to testing sites and its association with timing of HIV diagnosis
Q58553186	Distinguishing Brain Impact of Aging and HIV Severity in Chronic HIV Using Multiparametric MR Imaging and MR Spectroscopy
Q34455423	Do people with HIV infection have a normal life expectancy in the era of combination antiretroviral therapy?
Q44464712	Dolutegravir--a promising antiretroviral in development
Q58290460	Dolutegravir: a new option for HIV treatment
Q33725024	Dolutegravir: clinical efficacy and role in HIV therapy
Q37679935	Drug interactions with antiretrovirals and warfarin
Q46926715	Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues
Q90191256	Druggable targets of the endocannabinoid system: Implications for the treatment of HIV-associated neurocognitive disorder
Q28550445	Early HAART Initiation May Not Reduce Actual Reproduction Number and Prevalence of MSM Infection: Perspectives from Coupled within- and between-Host Modelling Studies of Chinese MSM Populations
Q51196202	Early antiretroviral therapy and potent second-line drugs could decrease HIV incidence of drug resistance.
Q36119499	Economic and epidemiological impact of early antiretroviral therapy initiation in India
Q40273442	Economic and public health consequences of delayed access to medical care for migrants living with HIV in France.
Q56910449	Effect of age at initiation of antiretroviral therapy on treatment outcomes; A retrospective cohort study at a large HIV clinic in southwestern Uganda
Q38058385	Effect of darunavir on lipid profile in HIV-infected patients
Q36715732	Effect of persistency of first-line HIV antiretroviral therapy on clinical outcomes
Q34596417	Effect of suberoylanilide hydroxamic acid (SAHA) administration on the residual virus pool in a model of combination antiretroviral therapy-mediated suppression in SIVmac239-infected indian rhesus macaques
Q26772160	Effectiveness and safety of traditional Chinese medicine in treating acquired immune deficiency syndrome: 2004-2014
Q44757517	Effectiveness of Mindfulness-Based Cognitive Therapy on the Quality of Life, Emotional Status, and CD4 Cell Count of Patients Aging with HIV Infection
Q40072531	Effectiveness, Safety, and Costs of a Treatment Switch to Dolutegravir Plus Rilpivirine Dual Therapy in Treatment-Experienced HIV Patients.
Q57166392	Effects of Discrimination on HIV-Related Symptoms in Heterosexual Men of Color
Q36347936	Effects of combined antiretroviral therapy on B- and T-cell release from production sites in long-term treated HIV-1+ patients
Q28660034	Effects of opiates and HIV proteins on neurons: the role of ferritin heavy chain and a potential for synergism
Q33650102	Efficacy of a Social Self-Value Empowerment Intervention to Improve Quality of Life of HIV Infected People Receiving Antiretroviral Treatment in Nepal: A Randomized Controlled Trial
Q53597147	Electrospun micelles/drug-loaded nanofibers for time-programmed multi-agent release.
Q36644877	Elevated Plasma Viral Loads in Romidepsin-Treated Simian Immunodeficiency Virus-Infected Rhesus Macaques on Suppressive Combination Antiretroviral Therapy
Q34634156	Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor
Q26829472	Engaging HIV care providers in conversations with their reproductive-age patients about fertility desires and intentions: a historical review of the HIV epidemic in the United States
Q42924252	Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment
Q36905526	Enhancing physical function in HIV-infected older adults: A randomized controlled clinical trial.
Q37604553	Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide
Q35214935	Estimating the impact of antiretroviral therapy: regional and global estimates of life-years gained among adults
Q41471847	Estimating trends in life expectancy in HIV-positive individuals
Q37155742	Estimation of HIV Seroprevalence in Colorectal Hospitals by Questionnaire Survey in Korea, 2002-2007.
Q88495370	Estimation of the Direct Cost of HIV-Infected Patients in Greece on an Annual Basis
Q38569706	Evaluating the Impact of a Pharmacist-Led Antiretroviral Stewardship Program on Reducing Drug Interactions in HIV-Infected Patients
Q40888736	Examining the Health Care Experiences of Women Living with Human Immunodeficiency Virus (HIV) and Perceived HIV-Related Stigma
Q35962509	Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria
Q36484214	Expanded HIV Testing and Linkage to Care: Conventional vs. Point-of-Care Testing and Assignment of Patient Notification and Linkage to Care to an HIV Care Program
Q35157015	Expanded HIV testing in low-prevalence, high-income countries: a cost-effectiveness analysis for the United Kingdom
Q28474271	Expanding HAART treatment to all currently eligible individuals under the 2008 IAS-USA Guidelines in British Columbia, Canada
Q33795242	Expenditures for the care of HIV-infected patients in rural areas in China's antiretroviral therapy programs.
Q33796944	Experiences of HIV-related stigma among young men who have sex with men.
Q47736687	Explaining recent mortality trends among younger and middle-aged White Americans.
Q64891436	Facilitators and Barriers Affecting Adherence Among People Living With HIV/AIDS: A Qualitative Perspective.
Q36450154	Factors Associated With Smoking Status among HIV-Positive Patients in Routine Clinical Care
Q28550940	Factors Associated with Low-Level Viraemia and Virological Failure: Results from the Austrian HIV Cohort Study
Q36649743	Factors Associated with Prescription of Opioids and Co-prescription of Sedating Medications in Individuals with HIV
Q36044073	Factors affecting clinician educator encouragement of routine HIV testing among trainees
Q44771900	Factors associated with HIV-positive women carrying pregnancies to term.
Q35071910	Factors associated with cancer incidence and with all-cause mortality after cancer diagnosis among human immunodeficiency virus-infected persons during the combination antiretroviral therapy era.
Q40356287	Factors associated with medication adherence in patients with human immunodeficiency virus in South Korea
Q36906674	Feasibility, acceptability and preliminary efficacy of an online peer-to-peer social support ART adherence intervention
Q30353427	Focus Group Evaluation of the LIVE Network-An Audio Music Program to Promote ART Adherence Self-Management.
Q91676298	Formulation and in-vivo Evaluation of Novel Topical Gel of Lopinavir for Targeting HIV
Q30925594	From pills to patients: an evaluation of data sources to determine the number of people living with HIV who are receiving antiretroviral therapy in Germany
Q37257522	Functional brain abnormalities during finger-tapping in HIV-infected older adults: a magnetoencephalography study
Q34016913	Functional impairment, disability, and frailty in adults aging with HIV-infection
Q99551924	Future approaches to clearing the latent human immunodeficiency virus reservoir: Beyond latency reversal
Q37115695	GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro
Q26786152	Gender difference in advanced HIV disease and late presentation according to European consensus definitions
Q33873986	Gender differences in clinical, immunological, and virological outcomes in highly active antiretroviral-treated HIV-HCV coinfected patients
Q38260902	Gene therapy for HIV infection.
Q35906631	Getting Personal: Progress and Pitfalls in HIV Prevention Among Latinas
Q38169292	Getting to zero HIV deaths: progress, challenges and ways forward
Q37838796	Growing Old with HIV.
Q38403063	Growing challenges for HIV programmes in Asia: clinic population trends, 2003-2013.
Q35648710	Gut epithelial barrier and systemic inflammation during chronic HIV infection
Q34315572	Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection
Q36748931	HCV monoinfection and HIV/HCV coinfection enhance T-cell immune senescence in injecting drug users early during infection
Q56447266	HIV & Hepatitis in the Americas 28-30 April 2016, Mexico City, Mexico
Q41712400	HIV 1-associated neurocognitive disorder: current epidemiology, pathogenesis, diagnosis and management
Q38400394	HIV Care Initiation Delay among Rural Residents in the Southeastern United States, 1996 to 2012.
Q36234850	HIV Clinical Pathway: A New Approach to Combine Guidelines and Sustainability of Anti-Retroviral Treatment in Italy
Q34150710	HIV Infection, Inflammation, Immunosenescence, and Aging
Q34152824	HIV Patient Characteristics that Affect Adherence to Exercise Programmes: An Observational Study
Q36642710	HIV Treatment and Prevention: A Simple Model to Determine Optimal Investment
Q36299305	HIV and Aging: Demographic Change in the Asia-Pacific Region
Q27016011	HIV and aging: emerging research issues
Q36147395	HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group
Q37777482	HIV and bone disease
Q38038201	HIV and dentistry in Australia: clinical and legal issues impacting on dental care
Q26852170	HIV and employment
Q38005046	HIV and inflammation: mechanisms and consequences
Q39903015	HIV and renal cell carcinoma: Experience in an Australian statewide HIV center
Q34894037	HIV and the Gastrointestinal Tract
Q45133583	HIV diagnoses are in our hands.
Q45182584	HIV disclosure in the workplace
Q42215138	HIV drug resistance in newly diagnosed adults in a rural prefecture of eastern China
Q35276630	HIV effects on age-associated neurocognitive dysfunction: premature cognitive aging or neurodegenerative disease?
Q53785021	HIV in 2010: potent antiretroviral drugs treat and sensitive assays monitor the infection; but there remain outstanding issues
Q90292121	HIV in Canada-Surveillance Report, 2018
Q26858824	HIV infection and older Americans: the public health perspective
Q36011567	HIV mother-to-child transmission, mode of delivery, and duration of rupture of membranes: experience in the current era
Q36186538	HIV pathogenesis: the host
Q38081072	HIV protease inhibitors in pregnancy : pharmacology and clinical use.
Q53665342	HIV quality of care assessment at an academic hospital: outcomes and lessons learned.
Q33828318	HIV testing trends: Southeastern Pennsylvania, 2002-2010.
Q41689945	HIV transmissions by stage and sex role in long-term concurrent sexual partnerships
Q60921365	HIV treatment regimens and adherence to national guidelines in Australia: an analysis of dispensing data from the Australian pharmaceutical benefits scheme
Q34689241	HIV, vascular and aging injuries in the brain of clinically stable HIV-infected adults: a (1)H MRS study
Q92833135	HIV-1 DNA-capture-seq is a useful tool for the comprehensive characterization of HIV-1 provirus
Q36412256	HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status
Q64091821	HIV-1 coreceptor tropism: A syllogistic connection with The Veterans Aging Cohort Study Index and the CD4/CD8 ratio
Q30679531	HIV-1 disease progression during highly active antiretroviral therapy: an application using population-level data in British Columbia: 1996-2011.
Q52613761	HIV-Infected Women Gain More Weight than HIV-Infected Men Following the Initiation of Antiretroviral Therapy.
Q40098055	HIV-associated mortality in the era of antiretroviral therapy scale-up - Nairobi, Kenya, 2015.
Q37971469	HIV-associated neurological disorders: a guide to pharmacotherapy
Q40090353	HIV-infected patients' beliefs about their chronic co-treatments in comparison with their combined antiretroviral therapy
Q44081416	HIV-negative gay men's perceived HIV risk hierarchy: imaginary or real?
Q40867242	HIV-related stigma and health-related quality of life among children living with HIV in Sweden
Q30414449	HIV-related stigma, isolation, discrimination, and serostatus disclosure: a global survey of 2035 HIV-infected adults
Q43461217	HIV-testing of men who have sex with men: variable testing rates among clinicians
Q37011927	HIV/AIDS, comorbidity, and alcohol: can we make a difference?
Q54263915	Harmful alcohol drinking among HIV-positive people in Nepal: an overlooked threat to anti-retroviral therapy adherence and health-related quality of life.
Q64100454	Harnessing CD8 T Cells Under HIV Antiretroviral Therapy
Q40579678	Health-related quality of life of patients on antiretroviral treatment in Botswana: A cross-sectional study
Q35946584	HealthMap: a cluster randomised trial of interactive health plans and self-management support to prevent coronary heart disease in people with HIV.
Q51748805	Heavy Cannabis Use Associated With Reduction in Activated and Inflammatory Immune Cell Frequencies in Antiretroviral Therapy-Treated Human Immunodeficiency Virus-Infected Individuals.
Q33399256	Hematological manifestations of human immunodeficiency virus infection and the effect of highly active anti-retroviral therapy on cytopenia
Q34405008	Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: a review.
Q37248836	High frequency of hypothalamic-pituitary-adrenal axis dysfunction after local corticosteroid injection in HIV-infected patients on protease inhibitor therapy
Q34776035	High levels of heterogeneity in the HIV cascade of care across different population subgroups in British Columbia, Canada
Q39344553	High prevalence of low skeletal muscle mass associated with male gender in midlife and older HIV-infected persons despite CD4 cell reconstitution and viral suppression
Q34075017	High rate of loss to clinical follow up among African HIV-infected patients attending a London clinic: a retrospective analysis of a clinical cohort
Q47136520	Highly specific reasons for nonadherence to antiretroviral therapy: results from the German adherence study
Q28537694	Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing
Q42735526	Hoffa's fat-pad inflammation in an HIV-positive patient
Q91228260	How do we preserve health among adults living with HIV?
Q33629458	Human Immunodeficiency Virus (HIV) Quality Indicators Are Similar Across HIV Care Delivery Models
Q37700004	Human immunodeficiency virus (HIV) in older people
Q40533645	Human papillomavirus 16 (HPV16) and HPV52 E6-specific immunity in HIV-infected adults on combination antiretroviral therapy.
Q55190039	Humanized Mice Engrafted With Human HSC Only or HSC and Thymus Support Comparable HIV-1 Replication, Immunopathology, and Responses to ART and Immune Therapy.
Q93070040	Hypertension among human immunodeficiency virus infected patients on treatment at Parirenyatwa Hospital: A descriptive study
Q57154655	Identifying factors associated with depression among men living with HIV/AIDS and undergoing antiretroviral therapy: a cross-sectional study in Heilongjiang, China
Q96229745	Identifying the role of PrimPol in TDF-induced toxicity and implications of its loss of function mutation in an HIV+ patient
Q37727880	Immune Responses in the Central Nervous System Are Anatomically Segregated in a Non-Human Primate Model of Human Immunodeficiency Virus Infection
Q42226567	Immune activation despite suppressive highly active antiretroviral therapy is associated with higher risk of viral blips in HIV-1-infected individuals
Q46854188	Immune restoration and onset of new AIDS-defining events with combination antiretroviral therapy in HIV type-1-infected immigrants in the Netherlands
Q98779076	Immunologic Response of HIV-Infected Children to Different Regimens of Antiretroviral Therapy: A Retrospective Observational Study
Q34638205	Immunologic basis of cardiovascular disease in HIV-infected adults
Q47643314	Impact of HIV Infection on Alpha-1 Antitrypsin in the Lung
Q36866613	Impact of HIV and aging on neuropsychological function
Q37077610	Impact of HIV-1 tropism on the emergence of non-AIDS events in HIV-infected patients receiving fully suppressive antiretroviral therapy
Q36763762	Impact of age on markers of HIV-1 disease
Q56889430	Impact of comorbidity on the risk and cost of hospitalization in HIV-infected patients: real-world data from Abruzzo Region
Q35316315	Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study
Q34405742	Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy.
Q45747193	Impact on life expectancy of late diagnosis and treatment of HIV-1 infected individuals: UK CHIC.
Q40299535	Implementation of HIV treatment as prevention strategy in 17 Canadian sites: immediate and sustained outcomes from a 35-month Quality Improvement Collaborative.
Q53730842	Improved life expectancy of people living with HIV: who is left behind?
Q35951760	Improved survival in HIV treatment programmes in Asia
Q33784743	Improving cervical cancer screening rates in an urban HIV clinic.
Q59791498	Improving overall health of children living with HIV through an oral health intervention in Cambodia: study protocol for a randomized controlled trial
Q38819109	In vitro fertilization when men, women, or both partners are positive for HIV: a case-control study
Q34062712	Incidence and risk factors for AIDS-related mortality in HIV patients in China: a cross-sectional study
Q55186790	Incidence of Antiretroviral Drug Interactions During Hospital Course: The Role of a Pharmacist-Led Antiretroviral Stewardship Program.
Q40203336	Incidence of Intermediate-stage Age-related Macular Degeneration in Patients With Acquired Immunodeficiency Syndrome
Q36323317	Incidence of Postsuppression Virologic Rebound in Perinatally HIV-Infected Asian Adolescents on Stable Combination Antiretroviral Therapy
Q47118049	Incidence of diabetes mellitus and factors associated with its development in HIV-positive patients over the age of 50.
Q27021524	Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions
Q42202635	Increased costs of HIV care associated with aging in an HIV-infected population.
Q47655423	Increased non-AIDS mortality among persons with AIDS-defining events after antiretroviral therapy initiation
Q57098021	Increased platelet reactivity in HIV-1-infected patients receiving abacavir-containing antiretroviral therapy
Q31066302	Increased prevalence and severity of radiographic hand osteoarthritis in patients with HIV-1 infection associated with metabolic syndrome: data from the cross-sectional METAFIB-OA study
Q33832012	Increased risk of fragility fractures among HIV infected compared to uninfected male veterans
Q37534052	Increased risk of serious non-AIDS-related events in HIV-infected subjects on antiretroviral therapy associated with a low CD4/CD8 ratio.
Q28473706	Increasing rates of obesity among HIV-infected persons during the HIV epidemic
Q33912595	Inflammation, Immune Activation, and Antiretroviral Therapy in HIV
Q87403846	Influences of Allocating HIV/AIDS Specialized Nurses on Clinical Outcomes in Japan
Q64078264	Inhibition of the thioredoxin system by PX-12 (1-methylpropyl 2-imidazolyl disulfide) impedes HIV-1 infection in TZM-bl cells
Q37139616	Initiation of antiretroviral therapy in youth with HIV: a U.S.-based provider survey
Q59360103	Inpatient Outcomes After Elective Lumbar Spinal Fusion for Patients with Human Immunodeficiency Virus in the Absence of Acquired Immunodeficiency Syndrome
Q92856907	Inpatient, Outpatient, and Pharmacy Costs in Patients With and Without HIV in the US Veteran's Affairs Administration System
Q58763014	Insulin Resistance in HIV-Patients: Causes and Consequences
Q35670873	Insulin resistance by homeostasis model assessment in HIV-infected patients on highly active antiretroviral therapy: cross-sectional study
Q36919443	Insurability of HIV-positive people treated with antiretroviral therapy in Europe: collaborative analysis of HIV cohort studies
Q40127748	Insurance status and mortality among patients with AIDS.
Q39464708	Integration of palliative care throughout HIV disease
Q40623733	Intensive adherence counselling for HIV-infected individuals failing second-line antiretroviral therapy in Johannesburg, South Africa
Q40699555	Intention-to-treat survival analysis of hepatitis C virus/human immunodeficiency virus coinfected liver transplant: Is it the waiting list?
Q36379299	Interleukin 10 responses are associated with sustained CD4 T-cell counts in treated HIV infection
Q38163422	Interleukin-21 and T follicular helper cells in HIV infection: research focus and future perspectives
Q38768887	Invited Commentary: A Landmark Study Launched in a Public Health Maelstrom.
Q84575625	Is HAART modifying the HIV epidemic?
Q37316732	Is HIV Painful? An Epidemiologic Study of the Prevalence and Risk Factors for Pain in HIV-infected Patients
Q33792651	Is HIV a model of accelerated or accentuated aging?
Q35505203	Is bone loss linked to chronic inflammation in antiretroviral-naive HIV-infected adults? A 48-week matched cohort study
Q39867464	Is the elimination of HIV infection within reach in the United States? Lessons from an epidemiologic transmission model
Q28649524	Kericho CLinic-based ART Diagnostic Evaluation (CLADE): design, accrual, and baseline characteristics of a randomized controlled trial conducted in predominately rural, district-level, HIV clinics of Kenya
Q36194823	Late HIV Diagnosis: Proposed Common Definitions and Associations With Short-Term Mortality
Q37644178	Late presentation increases risk and costs of non-infectious comorbidities in people with HIV: an Italian cost impact study
Q81703395	Life and death in the cART era
Q34667707	Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies
Q41377430	Life expectancy among HIV-positive patients in Rwanda: a retrospective observational cohort study
Q64903981	Life expectancy and disparities in survival among HIV-infected people receiving antiretroviral therapy: an observational cohort study in Kathmandu, Nepal.
Q95360885	Life expectancy and years of life lost in HIV patients under the care of BandarAbbas Behavioral Disorders Counseling Center
Q37636104	Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population
Q22248095	Life expectancy of HIV-positive adults: a review
Q35693918	Life expectancy of HIV-positive individuals on combination antiretroviral therapy in Canada
Q38405857	Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta-analysis
Q39590922	Life expectancy trends in adults on antiretroviral treatment in South Africa
Q90644707	Life-Expectancy Disparities Among Adults With HIV in the United States and Canada: The Impact of a Reduction in Drug- and Alcohol-Related Deaths Using the Lives Saved Simulation Model
Q37256266	Lifetime suicide attempt history, quality of life, and objective functioning among HIV/AIDS patients with alcohol and illicit substance use disorders
Q35148915	Lipodystrophy: pathophysiology and advances in treatment
Q38575356	Live attenuated herpes zoster vaccine for HIV-infected adults
Q37290659	Lives saved by expanding HIV treatment availability in resource-limited settings: the example of Haiti
Q33803473	Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI
Q42278643	Long-term suppressive combined antiretroviral treatment does not normalize the serum level of soluble CD14.
Q31106702	Long-term survival in HIV positive patients with up to 15 Years of antiretroviral therapy
Q44793892	Longitudinal assessment of cardiac diastolic function in HIV-infected patients
Q35382383	Loss of protease dimerization inhibition activity of darunavir is associated with the acquisition of resistance to darunavir by HIV-1.
Q36816616	Low Prolactin and High 20-α-Hydroxysteroid Dehydrogenase Levels Contribute to Lower Progesterone Levels in HIV-Infected Pregnant Women Exposed to Protease Inhibitor-Based Combination Antiretroviral Therapy
Q37629445	Low back pain and associated imaging findings among HIV-infected patients referred to an HIV/palliative care clinic
Q47121833	Low-level genital HIV shedding in Thai HIV-infected women with suppressed plasma viral load after menopause: a longitudinal study
Q57815879	Magnitude and associated factors of diabetes mellitus and hypertension among adult HIV-positive individuals receiving highly active antiretroviral therapy at Jugal Hospital, Harar, Ethiopia
Q35557252	Management of Pneumocystis Jirovecii pneumonia in HIV infected patients: current options, challenges and future directions
Q37899071	Management of fat accumulation in patients with HIV infection
Q36933984	Management of human immunodeficiency virus infection in advanced age.
Q50928686	Mapping abnormal subcortical brain morphometry in an elderly HIV+ cohort.
Q26785536	Measures of Quality of Care for People with HIV: A Scoping Review of Performance Indicators for Primary Care
Q89766245	Measuring multimorbidity beyond counting diseases: systematic review of community and population studies and guide to index choice
Q42638904	Mechanisms of CNS Viral Seeding by HIV+ CD14+ CD16+ Monocytes: Establishment and Reseeding of Viral Reservoirs Contributing to HIV-Associated Neurocognitive Disorders
Q34813144	Medical ICU admission diagnoses and outcomes in human immunodeficiency virus-infected and virus-uninfected veterans in the combination antiretroviral era
Q39305182	Mental Health Experiences of Older Adults Living with HIV: Uncertainty, Stigma, and Approaches to Resilience
Q64974407	Mind Matters: Treatment Concerns Predict the Emergence of Antiretroviral Therapy Side Effects in People with HIV.
Q60640918	Mindfulness-Based Cognitive Therapy application for People Living with Chronic Disease: the case of HIV
Q37086075	Missed office visits and risk of mortality among HIV-infected subjects in a large healthcare system in the United States
Q92586273	Mitochondrial DNA somatic mutation burden and heteroplasmy are associated with chronological age, smoking, and HIV infection
Q35680087	Mitral Annular and Coronary Artery Calcification Are Associated with Mortality in HIV-Infected Individuals
Q36242558	Modeling the Mechanisms by Which HIV-Associated Immunosuppression Influences HPV Persistence at the Oral Mucosa
Q28551803	Modeling the Slow CD4+ T Cell Decline in HIV-Infected Individuals
Q34207356	Modelling clinical progression and health care utilization of HIV-positive patients in British Columbia prior to death
Q33349016	Models of accelerated sarcopenia: critical pieces for solving the puzzle of age-related muscle atrophy
Q44324472	Morbidity and mortality in HIV infection
Q36948126	Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study
Q40868698	Mortality Risk After AIDS-Defining Opportunistic Illness Among HIV-Infected Persons--San Francisco, 1981-2012.
Q35175798	Mortality among antiretroviral-eligible patients in an urban public clinic
Q28475331	Mortality of HIV-infected patients starting antiretroviral therapy in sub-Saharan Africa: comparison with HIV-unrelated mortality
Q28551895	Mortality, Causes of Death and Associated Factors Relate to a Large HIV Population-Based Cohort
Q35819368	Multimodal neuroimaging evidence of alterations in cortical structure and function in HIV-infected older adults.
Q33706218	Multiple cause-of-death data among people with AIDS in Italy: a nationwide cross-sectional study.
Q60046427	Multivariate Computational Analysis of Gamma Delta T Cell Inhibitory Receptor Signatures Reveals the Divergence of Healthy and ART-Suppressed HIV+ Aging
Q44766920	NYVAC immunization induces polyfunctional HIV-specific T-cell responses in chronically-infected, ART-treated HIV patients
Q36444419	Nadir CD4+, religion, antiretroviral therapy, incidence of type 2 diabetes mellitus, and increasing rates of obesity among black Africans with HIV disease
Q33668524	Narrowing the Gap in Life Expectancy Between HIV-Infected and HIV-Uninfected Individuals With Access to Care
Q37229639	Navigating identity, territorial stigma, and HIV care services in Vancouver, Canada: A qualitative study
Q34354576	Net financial benefits of averting HIV infections among people who inject drugs in Urumqi, Xinjiang, Peoples Republic of China (2005-2010).
Q89013441	Neurocognitive functioning predicts frailty index in HIV
Q38732228	Neuroimaging with magnetoencephalography: A dynamic view of brain pathophysiology
Q47604267	Neurological manifestations, laboratory and neuroimaging features in HIV-infected patients
Q38882614	Neurotoxicity in the Post-HAART Era: Caution for the Antiretroviral Therapeutics
Q38811470	No Decrease in Knee Survivorship or Outcomes Scores for Patients With HIV Infection Who Undergo TKA.
Q39793553	No viral evolution in the lymph nodes of simian immunodeficiency virus-infected rhesus macaques during combined antiretroviral therapy
Q36242636	Non-Communicable Disease Preventive Screening by HIV Care Model
Q36404797	Non-HIV-related health care utilization, demographic, clinical and laboratory factors associated with time to initial retention in HIV care among HIV-positive individuals linked to HIV care
Q64137244	Noncommunicable diseases among HIV-infected persons in low-income and middle-income countries: a systematic review and meta-analysis
Q30609066	Noninfectious Diarrhea in HIV Seropositive Individuals: a Review of Prevalence Rates, Etiology, and Management in the Era of Combination Antiretroviral Therapy
Q83731557	Not so SMART?
Q34045363	Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.
Q37385347	Novel targets for antiretroviral therapy: clinical progress to date
Q39453985	Nucleoside reverse transcriptase inhibitor-reducing strategies in HIV treatment: assessing the evidence
Q30979829	Obesity Among HIV-Infected Adults Receiving Medical Care in the United States: Data From the Cross-Sectional Medical Monitoring Project and National Health and Nutrition Examination Survey
Q39851345	Online resources for persons recently diagnosed with HIV/AIDS: an analysis of HIV-related webpages
Q47607790	Ophthalmologic Disease in HIV Infection: Recent Changes in Pathophysiology and Treatment
Q37405336	Optimal use of raltegravir (Isentress(R)) in the treatment of HIV-infected adults - Canadian consensus guidelines.
Q35770863	Optimizing adherence to antiretroviral therapy
Q37240766	Optimum time to start antiretroviral therapy during HIV-associated opportunistic infections
Q37617835	Oral health associated with quality of life of people living with HIV/AIDS in Brazil
Q38067660	Organ Transplantation and HIV Progress or Success? A Review of Current Status
Q37515418	Organic cation transporters and their roles in antiretroviral drug disposition
Q58204653	Outcome of HCV/HIV-Coinfected Liver Transplant Recipients: A Prospective and Multicenter Cohort Study
Q36953309	Overload: impact of incident stressful events on antiretroviral medication adherence and virologic failure in a longitudinal, multisite human immunodeficiency virus cohort study
Q30249677	Overview of HIV molecular epidemiology among people who inject drugs in Europe and Asia.
Q94570788	Overweight and Obesity among Recipients of Antiretroviral Therapy at HIV Clinics in Gaborone, Botswana: Factors Associated with Change in Body Mass Index
Q37457987	Pain is independently associated with impaired physical function in HIV-infected patients
Q36282679	Pain, mood, and substance abuse in HIV: implications for clinic visit utilization, antiretroviral therapy adherence, and virologic failure
Q38807176	Past, Present, and Future Drug Delivery Systems for Antiretrovirals
Q35929429	Patient-Reported Symptoms Over 48 Weeks in a Randomized, Open-Label, Phase IIIb Non-Inferiority Trial of Adults with HIV Switching to Co-Formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF versus Continuation of Non-Nucleoside Rever
Q33719226	Patients present earlier and survival has improved, but pre-ART attrition is high in a six-year HIV cohort data from Ethiopia.
Q47644581	Patients' perspectives on the development of HIV services to accommodate ageing with HIV: a qualitative study
Q47150619	Patterns of patient and healthcare provider viewpoints regarding participation in HIV cure-related clinical trials. Findings from a multicentre French survey using Q methodology (ANRS-APSEC).
Q47622555	Perceived social support, hope, and quality of life of persons living with HIV/AIDS: a case study from Nepal
Q34978379	Performance of a mathematical model to forecast lives saved from HIV treatment expansion in resource-limited settings
Q39334000	Perioperative concerns in neurosurgical patients with human immunodeficiency virus infection
Q36440262	Persistent Immune Activation and Carotid Atherosclerosis in HIV-Infected Ugandans Receiving Antiretroviral Therapy
Q37591592	Personalized life expectancy and treatment benefit index of antiretroviral therapy
Q37622276	Perspectives of middle-aged African-American women in the Deep South on antiretroviral therapy adherence
Q26772852	Perspectives on menopause and women with HIV
Q37251569	Pharmacogenetics of nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathy
Q44938963	Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects
Q21562140	Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials
Q64069131	Physicians' patient base composition and mortality among people living with HIV who initiated antiretroviral therapy in a universal care setting
Q34452479	Pneumococcal vaccination among HIV-infected adult patients in the era of combination antiretroviral therapy
Q34037407	Polypharmacy in the HIV-infected older adult population
Q36925430	Population-Based Estimates of Life Expectancy After HIV Diagnosis: United States 2008-2011.
Q35789353	Population-based human immunodeficiency virus 1 drug resistance profiles among individuals who experienced virological failure to first-line antiretroviral therapy in Henan, China during 2010-2011
Q50626704	Post-traumatic growth as outcome of a cognitive-behavioural therapy trial for motor vehicle accident survivors with PTSD.
Q34629153	Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study
Q33939058	Post-trial access to antiretrovirals: who owes what to whom?
Q36603416	Potential benefit of dolutegravir once daily: efficacy and safety
Q43431767	Prediction of health preference values from CD4 counts in individuals with HIV.
Q40060299	Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach
Q36747893	Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis
Q37102206	Predictors and Profiles of Antiretroviral Therapy Adherence Among African American Adolescents and Young Adult Males Living with HIV.
Q34320356	Predictors of Loss to follow-up in Patients Living with HIV/AIDS after Initiation of Antiretroviral Therapy
Q41426517	Predictors of immunological failure and determinants of suboptimal CD4 testing among adults with HIV on first-line antiretroviral therapy in Andhra Pradesh, India, 2008-2011.
Q36664055	Predictors of linkage to care following community-based HIV counseling and testing in rural Kenya
Q92481120	Predictors of primary non-adherence to concomitant chronic treatment in HIV-infected patients with antiretroviral therapy
Q36386810	Preferred antiretroviral drugs for the next decade of scale up.
Q51000618	Premature age-related comorbidities among HIV-infected persons compared with the general population.
Q39474417	Premature and accelerated aging: HIV or HAART?
Q41644248	Pretreatment HIV-1 drug resistance to first-line drugs: results from a baseline assessment of a large cohort initiating ART in Vietnam, 2009-10.
Q35937597	Prevalence and Correlates of Smoking and Readiness to Quit Smoking in People Living with HIV in Austria and Germany
Q33417606	Prevalence and correlates of cytopenias in HIV-infected adults initiating highly active antiretroviral therapy in Uganda
Q28391933	Prevalence and determinants of insufficient work ability in older HIV-positive and HIV-negative workers
Q38954399	Prevalence of Internalized HIV-Related Stigma Among HIV-Infected Adults in Care, United States, 2011-2013.
Q51299240	Prevalence of cardiovascular diseases in HIV-infected outpatients: results from a prospective, multicenter cohort study.
Q41227651	Prevalence of intermediate-stage age-related macular degeneration in patients with acquired immunodeficiency syndrome
Q45285345	Prevalence, clinical associations, and impact of intimate partner violence among HIV-infected gay and bisexual men: a population-based study.
Q37272968	Primary care of women aging with HIV.
Q33895875	Priorities for screening and treatment of latent tuberculosis infection in the United States
Q34640731	Process monitoring of an HIV treatment as prevention program in British Columbia, Canada
Q36164175	Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal
Q36198858	Promoting cancer prevention and control in community-based HIV/AIDS service organizations: are they ready?
Q42677061	Promoting long-acting reversible contraceptives and HIV testing: more work for harassed GPs?
Q35689846	Prospective memory deficits are associated with unemployment in persons living with HIV infection
Q51914156	Psychosocial snapshots: perinatally infected HIV+ adolescents' sexual behaviors and pregnancies.
Q57226268	Pulmonary Toxoplasmosis, a Rare but Severe Manifestation of a Common Opportunistic Infection in Late HIV Presenters: Report of Two Cases
Q91720531	Quadruple versus triple combination antiretroviral therapies for treatment naive people with HIV: systematic review and meta-analysis of randomised controlled trials
Q48039689	Quality of life of people living with HIV/AIDS treated by the specialized service in Vitória-ES, Brazil
Q64227157	Quantitative ultrasonometry: An alternative and easy method to evaluate bone quality in people living with human immunodeficiency virus
Q36706298	Racial-ethnic differences in all-cause and HIV mortality, Florida, 2000-2011.
Q24186953	Raltegravir for the treatment of HIV infection in adults and children
Q43300652	Raltegravir: a new choice in HIV and new chances for research
Q40725400	Randomized Controlled Trial: 4 Month versus 6 Month Monitoring of HIV-infected Patients on Highly Active Antiretroviral Therapy
Q38873020	Rates of Serious Infections in HIV-Infected Patients Receiving Tumor Necrosis Factor Inhibitor Therapy for Concomitant Autoimmune Diseases.
Q42556268	Rates of new infections in British Columbia continue to decline at a faster rate than in other Canadian regions
Q38262470	Reaching the unreached: treatment as prevention as a workable strategy to mitigate HIV and its consequences in high-risk groups
Q88300249	Realizing Women Living with HIV's Reproductive Rights in the Era of ART: The Negative Impact of Non-consensual HIV Disclosure on Pregnancy Decisions Amongst Women Living with HIV in a Canadian Setting
Q37779092	Recent advances in antiretroviral drugs
Q34394987	Reconstitution of intestinal CD4 and Th17 T cells in antiretroviral therapy suppressed HIV-infected subjects: implication for residual immune activation from the results of a clinical trial
Q41590742	Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial
Q38851684	Reducing rates of preventable HIV/AIDS-associated mortality among people living with HIV who inject drugs
Q39697959	Reductions in all-cause and cause-specific mortality among HIV-infected individuals receiving antiretroviral therapy in British Columbia, Canada: 2001-2012
Q44098476	Regional and temporal changes in HIV-related mortality in British Columbia, 1987-2006.
Q34388139	Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: the EuroSIDA study
Q36573561	Regulatory T Cells, Frailty, and Immune Activation in Men Who Have Sex With Men in the Multicenter AIDS Cohort Study
Q34547116	Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals--the Swiss HIV Cohort Study
Q34020121	Residual immune dysregulation syndrome in treated HIV infection
Q37431433	Resilience and Life Expectations of Perinatally HIV-1 Infected Adolescents in France
Q30431484	Response to the AIDS pandemic--a global health model
Q35788262	Retention in HIV Care and Predictors of Attrition from Care among HIV-Infected Adults Receiving Combination Anti-Retroviral Therapy in Addis Ababa
Q84565639	Rilpivirine: a step forward in tailored HIV treatment
Q64063286	Risk and Cost Associated With Drug-Drug Interactions Among Aging HIV Patients Receiving Combined Antiretroviral Therapy in France
Q53675040	Risk factors associated with older age in treatment-naive HIV-positive patients.
Q33897770	Risk factors for delayed antiretroviral therapy initiation among HIV-seropositive patients.
Q35661739	Risk factors for early mortality after AIDS in the cART era: A population-based cohort study in Italy
Q33609481	Risk of Acute Liver Injury With Antiretroviral Therapy by Viral Hepatitis Status
Q34336508	Risk of HIV transmission from patients on antiretroviral therapy: a position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy
Q34651525	Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review
Q34415980	Risk of diabetes mellitus in persons with and without HIV: a Danish nationwide population-based cohort study
Q41532601	Risk of non-AIDS-defining events among HIV-infected patients not yet on antiretroviral therapy
Q92424099	Rod-shape theranostic nanoparticles facilitate antiretroviral drug biodistribution and activity in human immunodeficiency virus susceptible cells and tissues
Q37762244	Role of interleukin-2 in patients with HIV infection
Q64109341	Role of pretreatment variables on plasma HIV RNA value at the sixth month of antiretroviral therapy including all first line drugs in HIV naïve patients: A path analysis approach
Q34920329	Routine HIV testing among hospitalized patients in Argentina. is it time for a policy change?
Q95650676	Routine HIV testing in acute care hospitals: Changing practice to curb a local HIV epidemic in Vancouver, BC
Q37228611	Rural residence and adoption of a novel HIV therapy in a national, equal-access healthcare system
Q106453158	SARS-CoV-2, SARS-CoV-1, and HIV-1 derived ssRNA sequences activate the NLRP3 inflammasome in human macrophages through a non-classical pathway
Q39251042	Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial
Q35087069	Safety and immunological responses to human mesenchymal stem cell therapy in difficult-to-treat HIV-1-infected patients
Q35623357	Safety and tolerability of varenicline tartrate (Champix(®)/Chantix(®)) for smoking cessation in HIV-infected subjects: a pilot open-label study
Q42243459	Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: the TRIP study
Q35557326	Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings
Q40565869	Screening and risk assessment for coronary artery disease in HIV infection: an unmet need
Q33847311	Self-reported adverse drug reactions and their influence on highly active antiretroviral therapy in HIV infected patients: a cross sectional study.
Q38749963	Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV Infection
Q37418140	Serious Non-AIDS events: Immunopathogenesis and interventional strategies
Q28541356	Severe morbidity according to sex in the era of combined antiretroviral therapy: the ANRS CO3 Aquitaine Cohort
Q35930699	Sex and Racial/Ethnic Differences in Premature Mortality Due to HIV: Florida, 2000-2009.
Q35589818	Short Communication: HIV RNA Levels Predict AIDS-Defining and Non-AIDS-Defining Cancers After Antiretroviral Therapy Initiation Among HIV-Infected Adults
Q35589825	Short Communication: Viral Suppression Is Associated with Increased Likelihood of Colorectal Cancer Screening Among Persons Living with HIV/AIDS.
Q83435702	Short- and long-term outcome of HIV-infected patients admitted to the intensive care unit
Q41899294	Short-term HIV-1 treatment interruption is associated with dysregulated TLR-stimuli responsiveness
Q37321845	Significant publications on infectious diseases pharmacotherapy in 2007.
Q37774819	Significant publications on infectious diseases pharmacotherapy in 2009.
Q38418110	Significant reduction in HIV virologic failure during a 15-year period in a setting with free healthcare access
Q34242798	Silence is not golden: invisible Latinas living with HIV in the Midwest
Q35158051	Single genome sequencing of HIV-1 gag and protease resistance mutations at virologic failure during the OK04 trial of simplified versus standard maintenance therapy
Q91599716	Single-Tablet Regimens in the Treatment of HIV-1 Infection
Q54204816	Sleeve Gastrectomy in Morbidly Obese HIV Patients: Focus on Anti-retroviral Treatment Absorption After Surgery.
Q38849176	Smoking Cessation for People Living With HIV/AIDS: A Literature Review and Synthesis
Q34823231	Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America
Q64067363	Social determinants of health and self-rated health status: A comparison between women with HIV and women without HIV from the general population in Canada
Q46885023	Socio-behavioral risk factors among older adults living with HIV in Thailand
Q41932161	Sociodemographic correlates of HIV drug resistance and access to drug resistance testing in British Columbia, Canada
Q37223591	Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes
Q39690321	Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus
Q43152952	Solid organ transplantation and HIV: A changing paradigm
Q34315579	Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment
Q35748552	Strong Impact of Smoking on Multimorbidity and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Individuals in Comparison With the General Population
Q46963527	Structural investigation of protonated azidothymidine and protonated dimer
Q35137873	Successful aging and the epidemiology of HIV.
Q88965051	Supervised Physical Activity and Improved Functional Capacity among Adults Living with HIV: A Systematic Review
Q38030898	Surgical management of bilateral parotid lipomatosis in a patient with HIV.
Q34063630	Survival outcomes and effect of early vs. deferred cART among HIV-infected patients diagnosed at the time of an AIDS-defining event: a cohort analysis
Q64970213	Switch rates, time-to-switch, and switch patterns of antiretroviral therapy in people living with human immunodeficiency virus in Japan, in a hospital-claim database.
Q28535141	Switching HIV treatment in adults based on CD4 count versus viral load monitoring: a randomized, non-inferiority trial in Thailand
Q38813848	Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens
Q37659742	Systematic review and meta-analysis of the adolescent HIV continuum of care in South Africa: the Cresting Wave.
Q34589562	Systematic review of HIV transmission between heterosexual serodiscordant couples where the HIV-positive partner is fully suppressed on antiretroviral therapy
Q26859971	T-cell aging in rheumatoid arthritis
Q37530464	Tackling HIV through robust diagnostics in the developing world: current status and future opportunities
Q34266259	Taming HIV-related inflammation with physical activity: a matter of timing
Q24620150	Targeted DNA mutagenesis for the cure of chronic viral infections
Q61812140	Targeted Mitochondrial COQ Delivery Attenuates Antiretroviral-Drug-Induced Senescence of Neural Progenitor Cells
Q35833324	Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells
Q64076275	Targeting the HIV-infected brain to improve ischemic stroke outcome
Q92006047	Temporal trends and black-white disparity in mortality among hospitalized persons living with HIV in the United States
Q35661732	Ten-year Survival by Race/Ethnicity and Sex Among Treated, HIV-infected Adults in the United States.
Q51213908	Ten-year mortality trends among persons diagnosed with HIV infection in England and Wales in the era of antiretroviral therapy: AIDS remains a silent killer.
Q41311570	Tenofovir alafenamide for HIV infection: is less more?
Q26774223	Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus
Q34050602	Th17, gut, and HIV: therapeutic implications
Q35580656	The 30-year war on AIDS: have we reached the tipping point?
Q40101352	The Aging Population with HIV Infection
Q29307877	The CD4:CD8 ratio is associated with markers of age-associated disease in virally suppressed HIV-infected patients with immunological recovery
Q40047379	The Canadian HIV and aging cohort study - determinants of increased risk of cardio-vascular diseases in HIV-infected individuals: rationale and study protocol.
Q53403249	The Clinic Environment as a Form of Social Support for Adolescents and Young Adults Living with HIV.
Q34779837	The Effects of Age and HIV on Neuropsychological Performance
Q36402466	The Epidemiologic and Economic Impact of Improving HIV Testing, Linkage, and Retention in Care in the United States
Q92900021	The HIV epidemic in Latin America: accomplishments and challenges on treatment and prevention
Q57166290	The HIV protease inhibitor, ritonavir, dysregulates human platelet function in vitro
Q35656027	The Impact of Marijuana Use on the Successful Aging of HIV-Infected Adults
Q46066001	The Importance of HIV Research for Transgender and Gender Non-Binary Individuals
Q36385925	The Influence of Trust in Physicians and Trust in the Healthcare System on Linkage, Retention, and Adherence to HIV Care
Q90274970	The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic
Q38056759	The MOTIVATE trials: maraviroc therapy in antiretroviral treatment-experienced HIV-1-infected patients
Q55514032	The RNA surveillance proteins UPF1, UPF2 and SMG6 affect HIV-1 reactivation at a post-transcriptional level.
Q33570363	The Surprising Role of Amyloid Fibrils in HIV Infection
Q37628307	The adolescent and young adult HIV cascade of care in the United States: exaggerated health disparities
Q37088310	The association between food insecurity and mortality among HIV-infected individuals on HAART.
Q57463885	The association of therapeutic versus recreational marijuana use and antiretroviral adherence among adults living with HIV in Florida
Q36187833	The burden of chronic diseases and cost-of-care in subjects with HIV infection in a Health District of Northern Italy over a 12-year period compared to that of the general population.
Q33940190	The cost-effectiveness of different feeding patterns combined with prompt treatments for preventing mother-to-child HIV transmission in South Africa: estimates from simulation modeling
Q36950527	The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men.
Q36843894	The cost-effectiveness of repeat HIV testing during pregnancy in a resource-limited setting
Q24655011	The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic
Q33813372	The dual impact of HIV-1 infection and aging on naïve CD4 T-cells: additive and distinct patterns of impairment
Q35962516	The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis
Q55020504	The effect of socioeconomic disadvantage on strategies to end the AIDS epidemic.
Q37815335	The effects of exercise training on metabolic and morphological outcomes for people living with HIV: a systematic review of randomised controlled trials
Q35337985	The first decade of antiretroviral therapy in Africa
Q38281773	The future role of CD4 cell count for monitoring antiretroviral therapy
Q36938539	The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial
Q34818798	The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial
Q35915467	The impact of HIV-associated anaemia on the incidence of red blood cell transfusion: implications for blood services in HIV-endemic countries
Q38559277	The impact of HIV-related stigma on the lives of HIV-positive women: an integrated literature review
Q37124151	The impact of mental health and traumatic life experiences on antiretroviral treatment outcomes for people living with HIV/AIDS
Q36137725	The impact of scaling-up combination antiretroviral therapy on patterns of mortality among HIV-positive persons in British Columbia, Canada
Q35804426	The influence of neurocognitive impairment on HIV treatment outcomes among drug-involved people living with HIV/AIDS.
Q40125887	The investigation of CD4+T-cell functions in primary HIV infection with antiretroviral therapy
Q38198106	The issues around opioid prescribing in HIV-related pain
Q47580980	The microbiome and HIV persistence: implications for viral remission and cure
Q37025385	The next therapeutic challenge in HIV: polypharmacy
Q33828458	The past, present, and future of HIV prevention: integrating behavioral, biomedical, and structural intervention strategies for the next generation of HIV prevention
Q41428049	The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age.
Q35013358	The potential impact of routine testing of individuals with HIV indicator diseases in order to prevent late HIV diagnosis
Q39216249	The relationship between body composition and knee structure in patients with human immunodeficiency virus.
Q35032433	The relationship between injection and noninjection drug use and HIV disease progression
Q34743643	The reliability of the modified lower extremity functional scale among adults living with HIV on antiretroviral therapy, in Rwanda, Africa.
Q42205021	The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy
Q38764695	The role of tenofovir alafenamide in future HIV management
Q42376651	The role of the glycosyl moiety of myricetin derivatives in anti-HIV-1 activity in vitro
Q99728002	The tetraspanin CD151 marks a unique population of activated human T cells
Q24597485	The treatment of patients with HIV
Q55355811	Thrive With Me: Protocol for a Randomized Controlled Trial to Test a Peer Support Intervention to Improve Antiretroviral Therapy Adherence Among Men Who Have Sex With Men.
Q40783234	Time to Viremia for Patients Taking their First Antiretroviral Regimen and the Subsequent Resistance Profiles
Q34156186	Tobacco smoking in HIV-infected versus general population in france: heterogeneity across the various groups of people living with HIV.
Q37593720	Tongue Inspection in TCM: Observations in a Study Sample of Patients Living with HIV.
Q34269272	Total daily pill burden in HIV-infected patients in the southern United States
Q34802684	Towards a combined prognostic index for survival in HIV infection: the role of 'non-HIV' biomarkers
Q37539083	Traditional but not HIV-related factors are associated with nonalcoholic fatty liver disease in Asian patients with HIV-1 infection
Q49717450	Trajectories of Episodic Disability in People Aging with HIV: A Longitudinal Qualitative Study.
Q35861579	Transition of adolescents with HIV to adult care: characteristics and current practices of the adolescent trials network for HIV/AIDS interventions.
Q37255627	Transplantation of selected or transgenic blood stem cells - a future treatment for HIV/AIDS?
Q39712911	Treating HIV-1 Infection: What Might the Future Hold?
Q42221842	Treatment as prevention: are Argentinean HIV care providers willing to adopt earlier antiretroviral therapy?
Q27023036	Treatment-related optimistic beliefs and risk of HIV transmission: a review of recent findings (2009-2012) in an era of treatment as prevention
Q37659815	Trends and level of control of hypertension among adults attending an ambulatory HIV clinic in Kampala, Uganda: a retrospective study
Q38641676	Trends in Malignancies among Korean Patients Infected with Human Immunodeficiency Virus in the Highly Active Antiretroviral Therapy Era.
Q35897529	Trends in birth weight and gestational age for infants born to HIV-infected, antiretroviral treatment-naive women in Malawi
Q36302796	Trends in clinical development timeframes for antiviral drugs launched in the UK, 1981-2014: a retrospective observational study
Q38851681	Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globe: comparisons with general population
Q35232696	Trends in reported AIDS defining illnesses (ADIs) among participants in a universal antiretroviral therapy program: an observational study
Q46079648	Trends in the San Francisco HIV Epidemic in the "Getting to Zero" Era.
Q58704921	Type I IFN signaling blockade by a PASylated antagonist during chronic SIV infection suppresses specific inflammatory pathways but does not alter T cell activation or virus replication
Q36501102	U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008.
Q37133847	Understanding HIV-positive patients' preferences for healthcare services: a protocol for a discrete choice experiment
Q34361941	Understanding how adherence goals promote adherence behaviours: a repeated measure observational study with HIV seropositive patients
Q91897730	Understanding the Fertility Desires and Intentions among HIV-Positive Men Living in Ontario: Survey Instrument Development and Validation
Q36325586	Uniquely altered transcripts are associated with immune preservation in HIV infection
Q58801172	University of North Carolina/Emory Center for Innovative Technology (iTech) for Addressing the HIV Epidemic Among Adolescents and Young Adults in the United States: Protocol and Rationale for Center Development
Q93239863	Using Financial Incentives to Improve Rates of Viral Suppression and Engagement in Care of Patients Receiving HIV Care at 3 Health Clinics in Louisiana: The Health Models Program, 2013-2016
Q34354318	Using two on-going HIV studies to obtain clinical data from before, during and after pregnancy for HIV-positive women
Q35541563	Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial
Q34806420	Utilization of dental care services among low-income HIV-positive persons receiving primary care in South Florida
Q42720721	Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy
Q36275141	Viability of primary osteoblasts after treatment with tenofovir alafenamide: Lack of cytotoxicity at clinically relevant drug concentrations
Q39154839	Vicriviroc: a CCR5 antagonist for treatment-experienced patients with HIV-1 infection
Q34613499	Viral hepatitis and rapid diagnostic test based screening for HBsAg in HIV-infected patients in rural Tanzania
Q35290298	Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy
Q42276682	Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation
Q55519161	Virological and immunological failure of HAART and associated risk factors among adults and adolescents in the Tigray region of Northern Ethiopia.
Q38050815	Virological efficacy and safety of antiretroviral therapy-switch to atazanavir-based regimen: a review of the literature
Q48043453	Visceral adipose tissue and carotid intima-media thickness in HIV-infected patients undergoing cART: a prospective cohort study.
Q91176656	What is the effect of self-identified HIV activism in willingness to participate in HIV cure-related clinical trials? Results from the ANRS-APSEC study
Q30391322	What's new for antiretroviral treatment in women with HIV
Q33548096	When to start antiretroviral therapy in resource-limited settings: a human rights analysis
Q35535576	Who Provides Primary Care? An Assessment of HIV Patient and Provider Practices and Preferences
Q33730038	Women, Aging, and HIV: Clinical Issues and Management Strategies
Q37380340	XVII International AIDS Conference: From Evidence to Action - Basic science
Q30568493	Years of potential life lost due to HIV infection and associated factors based on national HIV surveillance data in Latvia, 1991-2010.
Q84935796	[Antiretroviral treatment of HIV-1 infection]
Q83044361	[Mucocutaneous infections in immunosuppression]

P356	DOI	10.1016/S0140-6736(08)61113-7
P8608	Fatcat ID	release_oajgbiijufgchc66yuy2vmolam
P3181	OpenCitations bibliographic resource ID	2013732
P932	PMC publication ID	3130543
P698	PubMed publication ID	18657708
P5875	ResearchGate publication ID	225033764

P50	author	Fiona C Lampe	Q62006742
P2093	author name string	The Antiretroviral Therapy Cohort Collaboration
P2860	cites work	Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators	Q29547281
		Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras	Q30482995
		Development and validation of a prognostic model for survival time data: application to prognosis of HIV positive patients treated with antiretroviral therapy	Q30947115
		Natural history of HIV infection in the era of combination antiretroviral therapy	Q33876280
		Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study	Q33989047
		Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy	Q34003391
		Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators.	Q34067875
		Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.	Q34068078
		Combination antiretroviral therapy and recent declines in AIDS incidence and mortality	Q34068458
		Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies	Q34139859
		Long-term HIV/AIDS survival estimation in the highly active antiretroviral therapy era.	Q34176854
		Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies	Q34228103
		The survival benefits of AIDS treatment in the United States	Q34533291
		HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis	Q34554560
		The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic	Q34554572
		Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users	Q34743004
		Migrants from sub-Saharan Africa in the Swiss HIV Cohort Study: a single center study of epidemiologic migration-specific and clinical features	Q36001277
		Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study	Q36247045
		Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies.	Q36285950
		Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection	Q36618299
		Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1-infected patients	Q36943004
		Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team	Q44088437
		Decline in deaths from AIDS due to new antiretrovirals	Q44184848
		Causes of death in HIV-infected French drug users, 1995-2000	Q44272212
		Efficacy and Durability of Nevirapine in Antiretroviral Drug Naïve Patients	Q44620203
		Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.	Q44752863
		Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study	Q44849439
		Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS.	Q45161155
		Changing spectrum of mortality due to human immunodeficiency virus: analysis of 260 deaths during 1995--1999.	Q45737669
		Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries	Q46391119
		Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.	Q46900196
		Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel	Q50105738
		Survival of persons with and without HIV infection in Denmark, 1995-2005.	Q50544706
		Declining HIV/AIDS mortality in New York City.	Q50644909
		Improved survival among HIV-infected individuals following initiation of antiretroviral therapy.	Q50908151
		Causes of death among HIV-infected patients in the era of highly active antiretroviral therapy, Bordeaux, France, 1998-1999.	Q51709478
		Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia	Q57259701
		There and back again: the impact of adult HIV prevalence on national life expectancies	Q57259731
		Clinical Outcome of Patients with HIV-1 Infection according to Immunologic and Virologic Response after 6 Months of Highly Active Antiretroviral Therapy	Q60199584
		Years of potential life lost due to HIV infection in the United States	Q64133531
		Years of potential life lost (YPLL)--what does it measure?	Q70259745
		Life expectancy of patients with newly-diagnosed HIV infection in the era of highly active antiretroviral therapy	Q79718322
P433	issue	9635
P407	language of work or name	English	Q1860
P921	main subject	life expectancy	Q188419
		collaboration	Q1145523
		anti-retroviral agent	Q50430310
P304	page(s)	293-9
P577	publication date	2008-07-26
P1433	published in	The Lancet	Q939416
P1476	title	Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies
P478	volume	372

Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies

scientific article

Reverse relations